The report provides a detailed analysis of the current myelodysplastic syndrome marketed drugs and late-stage pipeline drugs.

There are molecular testing gaps in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) treatment, highlighting ...

Advances in blood stem cell transplants now make it possible for people with blood cancers to get safe and effective ...

Geron Corporation (NASDAQ:GERN) is one of the best low priced pharma stocks to buy now. Earlier on May 28, Geron Corporation ...

Pune: A 70-year-old woman from Mumbai, misdiagnosed with myelodysplastic syndromes (MDS), a type of blood cancer specifically ...

During a live event, Thomas LeBlanc, MD, MA, discussed dose escalation of luspatercept in myelodysplastic syndromes and ...

The table below is a review of notable updates that occurred in June 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage. Drug ...

A panelist emphasizes that treatment decisions for anemia in low-risk myelodysplastic syndrome should be guided by symptoms ...

Dr. Mika Kontro, MD, PhD, will deliver a presentation titled "Efficacy of Macrophage Checkpoint Clever-1 Inhibition with ...

I’ve survived rare blood cancer for 15 years, but the lasting side effects have taken a toll — even so, I still find purpose, ...

Cullinan's innovative approach and Zipalertinib's potential approval in 2026 position it as a promising biotech investment.

A UVA Cancer Center study shows that blood cancer patients who receive partially matched stem cell transplants have survival ...